Welcome to our dedicated page for SHOULDER INNOVATIONS SEC filings (Ticker: SI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shoulder Innovations filings document a Delaware medical technology issuer focused on shoulder arthroplasty implants and related surgical-care technologies. Form 8-K reports cover operating results, Regulation FD disclosures, product-launch announcements, FDA-cleared indications, strategic partnership announcements, and material agreements tied to corporate facilities.
Governance filings include the definitive proxy statement for the annual meeting, director elections, board committee matters, non-employee director compensation, and stockholder voting procedures. Current reports also record director appointments, resignations, independence determinations, indemnification arrangements and other corporate-governance events.
SHOULDER INNOVATIONS, INC. (SI) reports that CEO & Executive Chairman Robert Joseph Ball exercised stock options to acquire 89,233 shares of Common Stock on September 14, 2026 at an exercise price of $2.0988 per share, from a fully vested, currently exercisable option expiring December 16, 2030. On the same date, he sold 10,175 shares of Common Stock at a weighted average price of $18.4478 per share, with sale prices ranging from $18.22 to $18.63; the disclosure states these shares were sold solely to cover the exercise price. The filing notes that his Common Stock holdings include 1,748 shares acquired on June 30, 2026 under the 2025 Employee Stock Purchase Plan, and no Rule 10b5-1 trading plan is reported.
SHOULDER INNOVATIONS, INC. (SI) received a Rule 144 notice from stockholder Robert Joseph Ball covering a proposed sale of up to 10,175 shares of common stock through Morgan Stanley Smith Barney LLC on or after September 14, 2026. The shares have an aggregate market value of $187,706.37 and are part of an outstanding total of 20,819,000 common shares. The shares to be sold were acquired for cash in private acquisitions from the issuer or an affiliate on March 6, 2025 (4,386 shares), June 20, 2025 (3,289 shares), and July 9, 2025 (2,500 shares).
SHOULDER INNOVATIONS, INC. (SI) insider Gilde Healthcare Holding B.V., a ten percent owner, reported an indirect open-market sale of 1,196 shares of common stock on 2026-08-26 at $22.60 per share. After this transaction, the reporting group’s indirect holdings total 2,185,914 shares, held through affiliated Gilde entities, with certain partners disclaiming full beneficial ownership.
SHOULDER INNOVATIONS, INC. (SI) reported insider activity by major shareholder Gilde Healthcare Holding B.V., related to shares held through Coöperatieve Gilde Healthcare V U.A. Over August 20–24, 2026, Gilde reported open-market sales totaling 25,097 shares of common stock at weighted average prices around $22.60–$22.78 per share. Voting and dispositive power over the sold shares resides with Gilde Healthcare V Management B.V., and certain individuals, including Geoff Pardo, disclaim beneficial ownership except to the extent of any pecuniary interest.
SHOULDER INNOVATIONS, INC. (SI) reported insider transactions by Chief Operating Officer Matthew Fraser Ahearn. On August 17–18, 2026, he sold a total of 22,500 shares of Common Stock in open-market transactions under a Rule 10b5-1 trading plan, at weighted average prices around $20–$21 per share across specified ranges. On August 14, 2026, he also made a bona fide gift of 2,500 shares of Common Stock.
Morgan Stanley Smith Barney LLC Executive Financial Services is listed as broker for the planned sale of 22,500 common shares of the issuer’s stock, with an indicated aggregate market value of $466,425.00 and 20,818,957 shares outstanding as of an intended sale date of 08/17/2026 on the NYSE. The shares were originally acquired in connection with a Preferred Equity Financing dated 11/17/2017. In the last three months, 10b5-1 plan sales for Matthew Ahearn included 4,144 common shares for $78,069.64 on 06/15/2026 and 15,856 common shares for $296,185.32 on 06/12/2026.
SHOULDER INNOVATIONS, INC. reports that Chief Commercial Officer Jonathan E. Osborne beneficially owns 60,355 shares of Common Stock directly. He also holds stock options over 24,870 shares at an exercise price of $2.48 expiring on July 12, 2034, 19,423 shares at $2.86 expiring on April 23, 2035, and 126,357 shares at $14.16 expiring on January 30, 2033. Footnotes describe graded vesting schedules, including options that vested one-fourth initially with the remainder vesting in 12 equal quarterly increments, and another grant vesting one-fourth annually on March 1 starting in 2027.
Shoulder Innovations, Inc., a commercial-stage medical technology company focused on the shoulder surgical care market, has promoted Jon Osborne to Chief Commercial Officer, effective August 6, 2026. He previously served as Vice President of Commercial Development and will now oversee all elements of the company’s commercial organization.
Osborne will work closely with the Customer Experience and Medical Education team to execute the company’s commercial strategy, emphasizing scaling the organization, deepening surgeon and partner relationships, and aligning commercial execution with the company’s innovation efforts. The company highlights his extensive orthopedic industry background and prior leadership roles at Smith & Nephew and other medical device firms.
Gilde Healthcare and related Dutch entities report holding an aggregate of 2,212,207 shares of Shoulder Innovations, Inc. common stock, representing 10.7% of the company. This percentage is based on 20,738,226 shares outstanding as of May 6, 2026, as stated in a Form 10-K filed May 13, 2026.
Gilde Healthcare is the record holder, while affiliated management entities may be deemed to share voting and dispositive power over these shares. The group also discloses recent open-market sales between July 30 and August 6, 2026, including 99,812 shares sold on August 4 at a weighted average price of $22.77 per share, with other smaller sales priced roughly between $22.60 and $23.73.